SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma trades jubilantly on reporting 41% rise in Q2 net profit

30 Oct 2014 Evaluate

Ajanta Pharma is currently trading at Rs. 1918.00, up by 104.65 points or 5.77% from its previous closing of Rs. 1813.35 on the BSE.

The scrip opened at Rs. 1827.00 and has touched a high and low of Rs. 1946.75 and Rs. 1821.00 respectively. So far 33178 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1946.75 on 30-Oct-2014 and a 52 week low of Rs. 848.90 on 30-Oct-2013.

Last one week high and low of the scrip stood at Rs. 1946.75 and Rs. 1805.00 respectively. The current market cap of the company is Rs. 6771.12 crore.

The promoters holding in the company stood at 73.83% while Institutions and Non-Institutions held 8.71% and 17.46% respectively.

Ajanta Pharma has reported 40.89% rise in its net profit at Rs 78.63 crore for the quarter under review as compared to Rs 55.81 crore for the same quarter in the previous year. Total income from operations of the company has increased 23.44% at Rs 353.20 crore for Q2FY15 as compared Rs 286.13 crore for the corresponding quarter previous year.

Ajanta Pharma is engaged in manufacturing pharmaceutical products. The company runs three divisions -- prescription drugs, OTC and institutional sales.

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×